BLOG DA SOCIEDADE
BRASILEIRA DE IMUNOLOGIA
Acompanhe-nos:

Translate

Mostrando postagens com marcador publicação. Mostrar todas as postagens
Mostrando postagens com marcador publicação. Mostrar todas as postagens

sexta-feira, 17 de maio de 2013

Assine a DORA e ajude a resgatar o brilho da ciência


Reproduzo abaixo o texto da San Francisco Declaration on Research Assessment (DORA), publicado hoje. Trata-se de reação da Sociedade Americana de Biologia Celular (ASCB, na sigla em inglês) e de um grupo de editores de periódicos científicos ao uso abusivo do fator de impacto na avaliação da produção acadêmica. 

O momento não poderia ser mais oportuno, tendo em vista o belo post de ontem do João Daher sobre o fechamento do laboratório da Polly Matzinger e os comentários que se seguiram, assim como textos anteriores recentes que trataram do tema da qualidade na produção científica (aqui e aqui).

Espero que tal declaração ajude a resgatar o brilho nos olhos de tantos cientistas massacrados que tenho visto por aqui. A impressão que tenho é aquela curiosidade nata, que deveria ser presente e borbulhante em quem "faz ciência", está abafada nessa geração que está sendo formada sob a pressão dos critérios de avaliação de seus orientadores. Como disse Adriana Bonomo em comentário no post de ontem, "critérios que esvaziam e não formam os novos de maneira sólida". 

E acaba ficando tudo tão boring (peço perdão pelo anglicismo): todo mundo estudando o mesmo tema e publicando sobre o mesmo assunto, over and over again, como escreveu o Bruce Alberts em editorial de hoje da Science:

Such metrics further block innovation because they encourage scientists to work in areas of science that are already highly populated, as it is only in these fields that large numbers of scientists can be expected to reference one's work, no matter how outstanding.

E aí, vamos todos assinar? 


San Francisco Declaration on Research Assessment

Putting science into the assessment of research

There is a pressing need to improve the ways in which the output of scientific research is evaluated by funding agencies, academic institutions, and other parties.

To address this issue, a group of editors and publishers of scholarly journals met during the Annual Meeting of The American Society for Cell Biology (ASCB) in San Francisco, CA, on December 16, 2012. The group developed a set of recommendations, referred to as the San Francisco Declaration on Research Assessment. We invite interested parties across all scientific disciplines to indicate their support by adding their names to this Declaration.

The outputs from scientific research are many and varied, including: research articles reporting new knowledge, data, reagents, and software; intellectual property; and highly trained young scientists. Funding agencies, institutions that employ scientists, and scientists themselves, all have a desire, and need, to assess the quality and impact of scientific outputs. It is thus imperative that scientific output is measured accurately and evaluated wisely.

The Journal Impact Factor is frequently used as the primary parameter with which to compare the scientific output of individuals and institutions. The Journal Impact Factor, as calculated by Thomson Reuters, was originally created as a tool to help librarians identify journals to purchase, not as a measure of the scientific quality of research in an article. With that in mind, it is critical to understand that the Journal Impact Factor has a number of well-documented deficiencies as a tool for research assessment. These limitations include: A) citation distributions within journals are highly skewed [1–3]; B) the properties of the Journal Impact Factor are field-specific: it is a composite of multiple, highly diverse article types, including primary research papers and reviews [1, 4]; C) Journal Impact Factors can be manipulated (or "gamed") by editorial policy [5]; and D) data used to calculate the Journal Impact Factors are neither transparent nor openly available to the public [4, 6, 7].

Below we make a number of recommendations for improving the way in which the quality of research output is evaluated. Outputs other than research articles will grow in importance in assessing research effectiveness in the future, but the peer-reviewed research paper will remain a central research output that informs research assessment. Our recommendations therefore focus primarily on practices relating to research articles published in peer-reviewed journals but can and should be extended by recognizing additional products, such as datasets, as important research outputs. These recommendations are aimed at funding agencies, academic institutions, journals, organizations that supply metrics, and individual researchers.

A number of themes run through these recommendations:

  • the need to eliminate the use of journal-based metrics, such as Journal Impact Factors, in funding, appointment, and promotion considerations;
  • the need to assess research on its own merits rather than on the basis of the journal in which the research is published; and
  • the need to capitalize on the opportunities provided by online publication (such as relaxing unnecessary limits on the number of words, figures, and references in articles, and exploring new indicators of significance and impact).

We recognize that many funding agencies, institutions, publishers, and researchers are already encouraging improved practices in research assessment. Such steps are beginning to increase the momentum toward more sophisticated and meaningful approaches to research evaluation that can now be built upon and adopted by all of the key constituencies involved.
The signatories of the San Francisco Declaration on Research Assessment support the adoption of the following practices in research assessment.

General Recommendation

1. Do not use journal-based metrics, such as Journal Impact Factors, as a surrogate measure of the quality of individual research articles, to assess an individual scientist's contributions, or in hiring, promotion, or funding decisions.

For funding agencies

2. Be explicit about the criteria used in evaluating the scientific productivity of grant applicants and clearly highlight, especially for early-stage investigators, that the scientific content of a paper is much more important than publication metrics or the identity of the journal in which it was published.

3. For the purposes of research assessment, consider the value and impact of all research outputs (including datasets and software) in addition to research publications, and consider a broad range of impact measures including qualitative indicators of research impact, such as influence on policy and practice.

For institutions

4. Be explicit about the criteria used to reach hiring, tenure, and promotion decisions, clearly highlighting, especially for early-stage investigators, that the scientific content of a paper is much more important than publication metrics or the identity of the journal in which it was published.

5. For the purposes of research assessment, consider the value and impact of all research outputs (including datasets and software) in addition to research publications, and consider a broad range of impact measures including qualitative indicators of research impact, such as influence on policy and practice.

For publishers

6. Greatly reduce emphasis on the journal impact factor as a promotional tool, ideally by ceasing to promote the impact factor or by presenting the metric in the context of a variety of journal-based metrics (e.g., 5-year impact factor, EigenFactor [8], SCImago [9], h-index, editorial and publication times, etc.) that provide a richer view of journal performance.

7. Make available a range of article-level metrics to encourage a shift toward assessment based on the scientific content of an article rather than publication metrics of the journal in which it was published.

8. Encourage responsible authorship practices and the provision of information about the specific contributions of each author.

9. Whether a journal is open-access or subscription-based, remove all reuse limitations on reference lists in research articles and make them available under the Creative Commons Public Domain Dedication [10].

10. Remove or reduce the constraints on the number of references in research articles, and, where appropriate, mandate the citation of primary literature in favor of reviews in order to give credit to the group(s) who first reported a finding.

For organizations that supply metrics

11. Be open and transparent by providing data and methods used to calculate all metrics.

12. Provide the data under a licence that allows unrestricted reuse, and provide computational access to data, where possible.

13. Be clear that inappropriate manipulation of metrics will not be tolerated; be explicit about what constitutes inappropriate manipulation and what measures will be taken to combat this.

14. Account for the variation in article types (e.g., reviews versus research articles), and in different subject areas when metrics are used, aggregated, or compared.

For researchers

15. When involved in committees making decisions about funding, hiring, tenure, or promotion, make assessments based on scientific content rather than publication metrics.

16. Wherever appropriate, cite primary literature in which observations are first reported rather than reviews in order to give credit where credit is due.

17. Use a range of article metrics and indicators on personal/supporting statements, as evidence of the impact of individual published articles and other research outputs [11].

18. Challenge research assessment practices that rely inappropriately on Journal Impact Factors and promote and teach best practice that focuses on the value and influence of specific research outputs.

References

  1. Adler, R., Ewing, J., and Taylor, P. (2008) Citation statistics. A report from the International Mathematical Union. www.mathunion.org/publications/report/citationstatistics0
  2. Seglen, P.O. (1997) Why the impact factor of journals should not be used for evaluating research. BMJ 314, 498–502.
  3. Editorial (2005). Not so deep impact. Nature 435, 1003–1004.
  4. Vanclay, J.K. (2012) Impact Factor: Outdated artefact or stepping-stone to journal certification. Scientometrics 92, 211–238.
  5. The PLoS Medicine Editors (2006). The impact factor game. PLoS Med 3(6): e291 doi:10.1371/journal.pmed.0030291.
  6. Rossner, M., Van Epps, H., Hill, E. (2007). Show me the data. J. Cell Biol. 179, 1091–1092.
  7. Rossner M., Van Epps H., and Hill E. (2008). Irreproducible results: A response to Thomson Scientific. J. Cell Biol. 180, 254–255.
  8. http://www.eigenfactor.org/
  9. http://www.scimagojr.com/
  10. http://opencitations.wordpress.com/2013/01/03/open-letter-to-publishers
  11. http://altmetrics.org/tools/


sexta-feira, 10 de maio de 2013

It's the Quality, not the Publon, Stupid!


Retomo o tema da qualidade na produção científica brasileira (recentemente tratada no SBlogI aqui e aqui) mas pretendo não focar a dicotomia qualidade vs quantidade. Até porque esta abordagem não me parece central. O fenômeno não é novo e se nutre de outros erros. O que hoje se chama “salami science” já foi mais elegantemente denominado de técnica de publicações de LPU (least publishable units) ou de publon, o menor quantum mensurável de publicação. O fato de publicar artigos curtos (e numerosos) não significa falta de qualidade. O problema é fazer este tipo de publicação comprometendo a qualidade apenas para ter um desempenho superior em avaliações também sem qualidade, por enfatizar excessivamente (para não dizer exclusivamente) a quantidade. 
O post de Dario (aqui) bastante oportuno, chamou a atenção para a necessária mudança nos nossos processos de avaliação de pesquisadores, tanto para financiamento quanto para concursos e também para as nossas deficiências de infra-estrutura. O que mais necessitamos para fazer ciência de alta qualidade?
Para além dos tópicos já citados, inequivocamente importantes, devemos lembrar dos grandes entraves burocráticos que temos: 
O regime de compras para pesquisa, e o de importações especialmente, obedece uma legislação inapropriada para as peculiaridades da prática científica. Vejam um texto do The Challenge of Establishing World Class Universities, (2009) de Jamil Salmi, do Banco Mundial: “University of São Paulo is the most selective institution in Brazil and it has “the highest number of top-rated graduate programmes, and every year it produces more PhD graduates than any US university”.; But he laments: “At the same time, its ability to manage its resources is constrained by rigid civil service regulations, even though it is the richest university in the country;
O regime de contratação de pessoal é também muito rígido o que dificulta formar equipes para projetos. 
A quase ausência de institucionalização das atividades de pesquisa também adiciona uma parcela importante de dificuldade. Um exemplo recente foi a falta de apoio institucional aos Institutos Nacionais de Ciência e Tecnologia (INCTs). A aprova dos INCTs aportarem um importante volume de recursos, muito poucas instituições ofereceram condições adequadas de operação aos Institutos nela sediados. O padrão majoritário foi um olímpico desconhecimento dos INCTs (acho que o COI ainda não bloqueou o uso do termo olímpico só o de Olim*íadas, mesmo que científicas)
Mas precisamos também olhar as nossas mazelas internas:
Porque não temos disciplinas oferecidas em língua inglesa para estimular o intercâmbio de estudantes? O domínio apropriado do inglês não é importante para os nossos estudantes, mesmo que não haja alunos estrangeiros na sala? Vejam o que Salmi fala a respeito das nossas Universidades: “It has very few linkages with the international research community, and only 3 per cent of its graduate students are from outside Brazil. The university is very inward-looking.” O mais grave é que ele se referia à USP, imaginem que esta percentagem é ainda mais baixa na demais universidades brasileiras. A ciência de ponta hoje exige a colaboração de muitos grupos, distribuídos em muito países, e baixo domínio do idioma inglês, lingua franca científica, não ajuda o nosso desenvolvimento;
Voltando ao ponto inicial, o da avaliação da produtividade individual, o que você acha da autoria graciosa? A inclusão de co-autores que não participaram efetivamente do trabalho não ajuda muito em identificar os verdadeiros autores, aqueles que contribuíram de forma genuína com o avanço do conhecimento científico e isto não depende de dinheiro, depende de leis …. internas e não escritas da comunidade científica. Voce já foi a uma das festas abaixo?
Créditos das ilustrações:
Salame (http://www.salami.li)

sexta-feira, 4 de janeiro de 2013

Paper de 2012 na Imunologia VIII

E, por último, minha sugestão de trabalho marcante do ano (que, diga-se de passagem, me foi primeiramente indicado pela colega de UFU, Profa. Neide Silva):


Mathur R, Oh H, Zhang D, Park SG, Seo J, Koblansky A, Hayden MS, Ghosh S.
Cell. 2012 Oct 26;151(3):590-602. doi: 10.1016/j.cell.2012.08.042.


Comentário:
Esse paper não traz 'novos atores' para o contexto, mas consegue demonstrar que conhecemos ainda muito pouco sobre a atuação dos receptores inatos. Com uma abordagem filogenética implícita, os autores demonstram primeiramente que flagelina de Salmonella typhimurium se liga e ativa TLR11. Depois, de forma surpreendente, os autores mostram que este receptor confere resistência a camundongos frente a infecção por Salmonella typhi - diferentemente de seres humanos, que não possuem tal receptor e são acometidos pela febre tifóide. Com tais dados, eles sugerem a utilização de camundongos TLR11-/- como um inédito modelo murino para o estudo da infecção.




quinta-feira, 3 de janeiro de 2013

Paper de 2012 na Imunologia VII

Sugestão do blogueiro Fredy Gutierrez


Shi CS, Shenderov K, Huang NN, Kabat J, Abu-Asab M, Fitzgerald KA, Sher A, Kehrl JH.
Nat Immunol. 2012 Jan 29;13(3):255-63. doi: 10.1038/ni.2215.

Comentário: 
"O artigo demonstra uma conexão direta entre autofagia e inflammassoma."



quarta-feira, 2 de janeiro de 2013

Paper de 2012 na Imunologia VI

Sugestão de João Viola:

van der Windt GJ, Everts B, Chang CH, Curtis JD, Freitas TC, Amiel E, Pearce EJ, Pearce EL. 
Immunity. 2012 Jan 27;36(1):68-78. doi: 10.1016/j.immuni.2011.12.007. 

Comentário:
"Os autores demonstram a diferença metabólica entre células T CD8 de memória e efetoras, mostrando que as células de memória utilizam preferencialmente a via mitocondrial aeróbica, enquanto as células efetoras utilizam a via glicolítica anaeróbica. Este efeito já foi bem demonstrado em células tumorais que apresentam uma alta taxa proliferativa, similar as células efetoras, chamado de efeito Warburg."




terça-feira, 1 de janeiro de 2013

Paper de 2012 na Imunologia V

Sugestão do blogueiro Bernardo Franklin


Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML. 
Neuron. 2012 Dec 6;76(5):908-20. doi: 10.1016/j.neuron.2012.10.029.




segunda-feira, 31 de dezembro de 2012

Paper de 2012 na Imunologia IV

Sugestão da blogueira Andréa Teixeira


An integrated encyclopedia of DNA elements in the human genome. The ENCODE Project Consortium et al., Nature. 2012 Sep 6;489(7414):57-74. doi: 10.1038/nature11247.





sábado, 29 de dezembro de 2012

Imunologia brasileira no Pubmed (21-28 dez/12)

Sent on Friday, 2012 December 28 
Search: ((brazil OR brasil[Affiliation])) AND (immune OR immunology OR imunologia)



PubMed Results
Items 1 - 32 of 32


1.A proposal for an alternative quality control test procedure for inactivated vaccines against food-and-mouth disease virus.
Molin-Capeti KC, Sepulveda L, Terra F, Torres-Pioli MF, Costa-Casagrande T, França SC, Thomaz-Soccol V.
Vaccine. 2012 Dec 22. doi:pii: S0264-410X(12)01753-7. 10.1016/j.vaccine.2012.12.001. [Epub ahead of print]
PMID: 23267841 [PubMed - as supplied by publisher]
2.Neutral and stable equilibria of genetic systems and the hardy-weinberg principle: limitations of the chi-square test and advantages of auto-correlation functions of allele frequencies.
Bosco F, Castro D, Briones MR.
Front Genet. 2012;3:276. doi: 10.3389/fgene.2012.00276. Epub 2012 Dec 19.
PMID: 23267365 [PubMed] Free Article
3.KIR genes and HLA class I ligands in Gaucher disease.
Vairo F, Portela P, Salim PH, Jobim M, Netto C, Dorneles A, Mittlestadt S, Jobim LF, Schwartz IV.
Gene. 2012 Dec 20. doi:pii: S0378-1119(12)01520-X. 10.1016/j.gene.2012.12.014. [Epub ahead of print]
PMID: 23266622 [PubMed - as supplied by publisher]
4.Angiotensin receptor blockers for bipolar disorder.
de Góis Queiroz AI, Medeiros CD, Ribeiro BM, de Lucena DF, Macêdo DS.
Med Hypotheses. 2012 Dec 19. doi:pii: S0306-9877(12)00524-5. 10.1016/j.mehy.2012.11.043. [Epub ahead of print]
PMID: 23265360 [PubMed - as supplied by publisher]
5.Case--control study of HLA-G promoter methylation status, HPV infection and cervical neoplasia in Curitiba, Brazil: a pilot analysis.
Gillio-Tos A, Bicalho MD, Fiano V, Grasso C, Tarallo V, Demarco L, Trevisan M, Xavier MB, Slowik R, Carvalho NS, Maestri CA, Lacerda HM, Zugna D, Richiardi L, Merletti F.
BMC Cancer. 2012 Dec 24;12(1):618. [Epub ahead of print]
PMID: 23265140 [PubMed - as supplied by publisher] Free Article
6.Trypanosoma cruzi extracellular amastigotes and host cell signaling: more pieces to the puzzle.
Ferreira ER, Bonfim-Melo A, Mortara RA, Bahia D.
Front Immunol. 2012;3:363. doi: 10.3389/fimmu.2012.00363. Epub 2012 Nov 30.
PMID: 23264776 [PubMed] Free PMC Article
7.Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination.
Vasconcelos JR, Dominguez MR, Araújo AF, Ersching J, Tararam CA, Bruna-Romero O, Rodrigues MM.
Front Immunol. 2012;3:358. doi: 10.3389/fimmu.2012.00358. Epub 2012 Dec 4.
PMID: 23264773 [PubMed] Free PMC Article
8.Haemophilus influenzae serotype b and a capsule-deficient type mutant (b-)invasive disease on a partially vaccinated child in Brazil.
Caldeira NG, de Filippis I, Catão Arruda T, Côrte Real ME, Batalha de Jesus A, de Almeida AE.
J Med Microbiol. 2012 Dec 21. [Epub ahead of print]
PMID: 23264458 [PubMed - as supplied by publisher]
9.Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer.
Nunes LM, Ayres FM, Francescantonio IC, Saddi VA, Avelino MA, Alencar RD, Silva RC, Meneghini AJ, Wastowski IJ.
Hum Immunol. 2012 Dec 18. doi:pii: S0198-8859(12)00650-7. 10.1016/j.humimm.2012.12.012. [Epub ahead of print]
PMID: 23261411 [PubMed - as supplied by publisher]
10.Higher cross-subtype IFN-γ ELISpot responses to Gag and Nef peptides in Brazilian HIV-1 subtype B- and F1- than in C-infected subjects.
Côrtes FH, Bello G, Vorsatz C, Pilotto JH, Guimarães ML, Grinsztejn B, Veloso VG, Pinto AR, Morgado MG.
Vaccine. 2012 Dec 19. doi:pii: S0264-410X(12)01793-8. 10.1016/j.vaccine.2012.12.023. [Epub ahead of print]
PMID: 23261042 [PubMed - as supplied by publisher]
11.The role of platelet-activating factor receptor (PAFR) in lung pathology during experimental malaria.
Lacerda-Queiroz N, Rachid MA, Teixeira MM, Teixeira AL.
Int J Parasitol. 2012 Dec 19. doi:pii: S0020-7519(12)00311-6. 10.1016/j.ijpara.2012.11.008. [Epub ahead of print]
PMID: 23260771 [PubMed - as supplied by publisher]
12.Moderate prevalence of transmitted drug-resistance mutations among antiretroviral-naïve HIV-infected pregnant women in Rio de Janeiro, Brazil.
Pilotto JH, Grinztejn B, Veloso VG, Velasque L, Friedman RK, Moreira RI, Rodrigues-Pedro A, Oliveira SM, Currier J, Morgado MG.
AIDS Res Hum Retroviruses. 2012 Dec 23. [Epub ahead of print]
PMID: 23259924 [PubMed - as supplied by publisher]
13.Local and systemic adverse effects of imiquimod therapy for external anogenital warts in men: report of three cases.
Rosenblatt A, de Campos Guidi HG.
Int J STD AIDS. 2012 Dec;23(12):909-10. doi: 10.1258/ijsa.2012.012076.
PMID: 23258837 [PubMed - in process]
14.Intrastromal injection of bevacizumab in patients with corneal neovascularization.
Vieira AC, Höfling-Lima AL, Gomes JÁ, Freitas Dd, Farah ME, Belfort R Jr.
Arq Bras Oftalmol. 2012 Aug;75(4):277-9.
PMID: 23258661 [PubMed - in process] Free Article
15.Exercise Improves the Th1 Response by Modulating Cytokine and NO Production in BALB/c Mice.
Terra R, Alves PJ, Gonçalves da Silva SA, Salerno VP, Dutra PM.
Int J Sports Med. 2012 Dec 20. [Epub ahead of print]
PMID: 23258605 [PubMed - as supplied by publisher]
16.Aspartic Protease Inhibitors: Effective Drugs against the Human Fungal Pathogen Candida albicans.
Santos AL, Braga-Silva LA.
Mini Rev Med Chem. 2012 Dec 5. [Epub ahead of print]
PMID: 23256485 [PubMed - as supplied by publisher]
17.Endemic pemphigus foliaceus: towards understanding autoimmune mechanisms of disease development.
Di Zenzo G, Zambruno G, Borradori L.
J Invest Dermatol. 2012 Nov;132(11):2499-502. doi: 10.1038/jid.2012.369.
PMID: 23069908 [PubMed - indexed for MEDLINE]
Related citations
18.The TGF-β pathway as an emerging target for Chagas disease therapy.
Araújo-Jorge TC, Waghabi MC, Bailly S, Feige JJ.
Clin Pharmacol Ther. 2012 Nov;92(5):613-21. doi: 10.1038/clpt.2012.102. Epub 2012 Sep 19. Review.
PMID: 22990752 [PubMed - indexed for MEDLINE]
Related citations
19.Cervical cancer in Latin America and the Caribbean: the problem and the way to solutions.
Villa LL.
Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1409-13. doi: 10.1158/1055-9965.EPI-12-0147.
PMID: 22956726 [PubMed - indexed for MEDLINE]
Related citations
20.Epidemiology and molecular characterization of hepatitis B virus infection in isolated villages in the Western Brazilian Amazon.
Castilho Mda C, Oliveira CM, Gimaque JB, Leão JD, Braga WS.
Am J Trop Med Hyg. 2012 Oct;87(4):768-74. doi: 10.4269/ajtmh.2012.12-0083. Epub 2012 Aug 20.
PMID: 22908032 [PubMed - indexed for MEDLINE]
Related citations
21.GLUT4 content decreases along with insulin resistance and high levels of inflammatory markers in rats with metabolic syndrome.
Leguisamo NM, Lehnen AM, Machado UF, Okamoto MM, Markoski MM, Pinto GH, Schaan BD.
Cardiovasc Diabetol. 2012 Aug 16;11:100. doi: 10.1186/1475-2840-11-100.
PMID: 22897936 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
22.Profile of Trypanosoma cruzi reactivity in a population at high risk for endemic pemphigus foliaceus (Fogo selvagem).
Sousa JX Jr, Diaz LA, Eaton DP, Hans-Filho G, Freitas EL, Delgado L, Ichimura LM, Cristaldi F, Orlandi R, Kesper N Jr, Umezawa ES, Rivitti EA, Aoki V; Cooperative Group on Fogo Selvagem Research.
Am J Trop Med Hyg. 2012 Oct;87(4):675-80. doi: 10.4269/ajtmh.2012.12-0206. Epub 2012 Jul 23.
PMID: 22826496 [PubMed - indexed for MEDLINE]
Related citations
23.Cytokine responses to novel antigens in a peri-urban population in Brazil exposed to Leishmania infantum chagasi.
Stober CB, Jeronimo SM, Pontes NN, Miller EN, Blackwell JM.
Am J Trop Med Hyg. 2012 Oct;87(4):663-70. doi: 10.4269/ajtmh.2012.12-0180. Epub 2012 Jul 23.
PMID: 22826477 [PubMed - indexed for MEDLINE]
Related citations
24.IgG autoantibody response against keratinocyte cadherins in endemic pemphigus foliaceus (fogo selvagem).
Flores G, Culton DA, Prisayanh P, Qaqish BF, James K, Maldonado M, Aoki V, Hans-Filho G, Rivitti EA, Diaz LA.
J Invest Dermatol. 2012 Nov;132(11):2573-80. doi: 10.1038/jid.2012.232. Epub 2012 Jul 19.
PMID: 22810308 [PubMed - indexed for MEDLINE]
Related citations
25.Activation of PPARγ by restores mast cell numbers and reactivity in alloxan-diabetic rats by reducing the systemic glucocorticoid levels.
Torres RC, Batista MM, Pons AH, Silva AR, Cordeiro RS, Martins MA, E Silva PM, Carvalho VF.
Eur J Pharmacol. 2012 Sep 15;691(1-3):261-7. doi: 10.1016/j.ejphar.2012.06.010. Epub 2012 Jun 16.
PMID: 22713549 [PubMed - indexed for MEDLINE]
Related citations
26.Evidence of multiple introductions of HIV-1 subtype C in Angola.
Afonso JM, Morgado MG, Bello G.
Infect Genet Evol. 2012 Oct;12(7):1458-65. doi: 10.1016/j.meegid.2012.05.005. Epub 2012 May 24.
PMID: 22634597 [PubMed - indexed for MEDLINE]
Related citations
27.Polymorphism of rotavirus genotype G1 in Brazil: in silico analysis of variant strains circulating in Rio de Janeiro from 1996 to 2004.
Maranhão AG, Vianez-Júnior JL, Benati FJ, Bisch PM, Santos N.
Infect Genet Evol. 2012 Oct;12(7):1397-404. doi: 10.1016/j.meegid.2012.04.018. Epub 2012 May 3.
PMID: 22579479 [PubMed - indexed for MEDLINE]
Related citations
28.Genetic and functional evaluation of the role of DLL1 in susceptibility to visceral leishmaniasis in India.
Mehrotra S, Fakiola M, Mishra A, Sudarshan M, Tiwary P, Rani DS, Thangaraj K, Rai M, Sundar S, Blackwell JM.
Infect Genet Evol. 2012 Aug;12(6):1195-201. doi: 10.1016/j.meegid.2012.04.017. Epub 2012 Apr 24.
PMID: 22561395 [PubMed - indexed for MEDLINE]
Related citations
29.Hepatitis B virus genotypes from European origin explains the high endemicity found in some areas from southern Brazil.
Bertolini DA, Gomes-Gouvêa MS, Carvalho-Mello IM, Saraceni CP, Sitnik R, Grazziotin FG, Laurindo JP, Fagundes NJ, Carrilho FJ, Pinho JR.
Infect Genet Evol. 2012 Aug;12(6):1295-304. doi: 10.1016/j.meegid.2012.04.009. Epub 2012 Apr 17.
PMID: 22538208 [PubMed - indexed for MEDLINE]
Related citations
30.Prevalence of feline leukemia virus infection in domestic cats in Rio de Janeiro.
de Almeida NR, Danelli MG, da Silva LH, Hagiwara MK, Mazur C.
J Feline Med Surg. 2012 Aug;14(8):583-6. doi: 10.1177/1098612X12444693. Epub 2012 Apr 5.
PMID: 22492347 [PubMed - indexed for MEDLINE]
Related citations
31.Increased miRNA-146a and miRNA-155 expressions in oral lichen planus.
Arão TC, Guimarães AL, de Paula AM, Gomes CC, Gomez RS.
Arch Dermatol Res. 2012 Jul;304(5):371-5. doi: 10.1007/s00403-011-1197-x. Epub 2011 Dec 4.
PMID: 22139425 [PubMed - indexed for MEDLINE]
Related citations
32.Salivary immunity in elderly individuals presented with Candida-related denture stomatitis.
Gasparoto TH, Sipert CR, de Oliveira CE, Porto VC, Santos CF, Campanelli AP, Lara VS.
Gerodontology. 2012 Jun;29(2):e331-9. doi: 10.1111/j.1741-2358.2011.00476.x. Epub 2011 Apr 1.
PMID: 21453417 [PubMed - indexed for MEDLINE]
Related citations

sexta-feira, 28 de dezembro de 2012

Paper de 2012 na Imunologia III

Sugestão da blogueira Cláudia Macaúbas.


Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. 
Raychaudhuri S, Sandor C, Stahl EA, Freudenberg J, Lee HS, Jia X, Alfredsson L, Padyukov L, Klareskog L, Worthington J, Siminovitch KA, Bae SC, Plenge RM, Gregersen PK, de Bakker PI. 
Nat Genet. 2012 Jan 29;44(3):291-6. doi: 10.1038/ng.1076.


Comentário:
"Este paper explora os milhares de genotipos HLA disponiveis (tanto de pacientes, neste caso com artrite reumatoide, quanto de controles) para deduzir exatamente os aminoacidos envolvidos na associacao do HLA com a doenca. Isto pode levar a avancos em se entender como exatamente antigenos do sistema HLA estariam envolvidos em doencas, por exemplo, usando este sistema para produzir moleculas mutantes e como estas moleculas ainda contribuem para o desenvolvimento da doenca."







quinta-feira, 27 de dezembro de 2012

Paper de 2012 na Imunologia II

Indicação de Julio Cesar Cetrulo Lorenzi

T cells become licensed in the lung to enter the central nervous system. 
Odoardi F, Sie C, Streyl K, Ulaganathan VK, Schläger C, Lodygin D, Heckelsmiller K, Nietfeld W, Ellwart J, Klinkert WE, Lottaz C, Nosov M, Brinkmann V, Spang R, Lehrach H, Vingron M, Wekerle H, Flügel-Koch C, Flügel A. 
Nature. 2012 Aug 30;488(7413):675-9. doi: 10.1038/nature11337.


Comentário:

"Na área de Esclerose Múltipla e seu modelo EAE, este artigo teve grande impacto uma fez que foi demonstrado no modelo de transferência adotiva de EAE, que os linfócitos transferidos, tem que obrigatoriamente passar pelo pulmão antes de invadir o CNS. A apresentação dos autores no congresso de neuroimmuno esse ano foi muito disputada as as imagens dos experimentos com 2photon não deixaram duvidas."



©SBI Sociedade Brasileira de Imunologia. Desenvolvido por: